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Abstract
Human adenoviruses from multiple species bind to coagulation factor X (FX), yet the importance of this interaction in
adenovirus dissemination is unknown. Upon contact with blood, vectors based on adenovirus serotype 5 (Ad5) binds to FX
via the hexon protein with nanomolar affinity, leading to selective uptake of the complex into the liver and spleen. The
Ad5:FX complex putatively targets heparan sulfate proteoglycans (HSPGs). The aim of this study was to elucidate the
specific requirements for Ad5:FX-mediated cellular uptake in this high-affinity pathway, specifically the HSPG receptor
requirements as well as the role of penton base-mediated integrin engagement in subsequent internalisation. Removal of
HS sidechains by enzymatic digestion or competition with highly-sulfated heparins/heparan sulfates significantly decreased
FX-mediated Ad5 cell binding in vitro and ex vivo. Removal of N-linked and, in particular, O-linked sulfate groups significantly
attenuated the inhibitory capabilities of heparin, while the chemical inhibition of endogenous HSPG sulfation dose-
dependently reduced FX-mediated Ad5 cellular uptake. Unlike native heparin, modified heparins lacking O- or N-linked
sulfate groups were unable to inhibit Ad5 accumulation in the liver 1h after intravascular administration of adenovirus.
Similar results were observed in vitro using Ad5 vectors possessing mutations ablating CAR- and/or av integrin binding,
demonstrating that attachment of the Ad5:FX complex to the cell surface involves HSPG sulfation. Interestingly, Ad5 vectors
ablated for av integrin binding showed markedly delayed cell entry, highlighting the need for an efficient post-attachment
internalisation signal for optimal Ad5 uptake and transport following surface binding mediated through FX. This study
therefore integrates the established model of av integrin-dependent adenoviral infection with the high-affinity FX-mediated
pathway. This has important implications for mechanisms that define organ targeting following contact of human
adenoviruses with blood.
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Introduction
Adenoviruses are non-enveloped, icosahedral double-stranded
DNA viruses of 70–90nm diameter. 54 different human serotypes
have been identified to date and are classified into species based on
their ability to agglutinate human, monkey or rat erythrocytes [1].
Adenoviruses cause a range of illnesses depending on the route of
initial infection, largely dictated by inherent adenoviral tropism.
These illnesses are usually self-limiting but can become potentially
life-threatening in certain circumstances. For example, species C
adenoviruses 1, 2 and 5 initially cause respiratory tract infections
after inhaled droplet transmission [2] but are associated with
fulminant hepatitis in bone marrow transplant patients [3,4].
Invasive adenovirus infection following liver transplant is relatively
common, occurring in approximately 10% of paediatric and 6% of
adult liver transplantion recipients (reviewed in [5]) and may be
due to latent donor-associated infection of the transplanted organ.
Adenovirus has also been detected in peripheral blood from
immunocompromised patients [6,7,8,9] a significant proportion of
whom then go on to develop potentially fatal disseminated
adenoviral disease. Taken together, these studies underline the
clinical significance of these common human pathogens. The
primary and secondary receptor systems used by adenoviruses for
cellular uptake following contact with different environments in
vivo are thus of particular interest and importance.
The species C adenovirus Ad5 can efficiently infect a wide
variety of cell types. In vitro studies have demonstrated that cell
tethering is mediated by a primary interaction of the Ad5 fiber
knob domain with the coxsackievirus and adenovirus receptor
(CAR; [10], reviewed in [11]), while the subsequent internalisation
of Ad5 particles is dependent on binding of avb3/avb5 integrins to
an RGD motif in the adenovirus penton base [12,13]. Several in
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vivo studies, however, have shown that direct interaction with CAR
is not required for uptake of Ad5 into the liver [14,15,16,17],
which is the primary target organ after contact of adenovirus with
the bloodstream in rodent models and in non-human primates
(reviewed in [18]). Moreover, CAR is now thought to be localised
primarily to tight junctions in intact epithelium, rendering it
inaccessible to viral particles (reviewed in [19]). Instead, recent
studies have demonstrated that uptake of Ad5 into the liver is
mediated by a high affinity interaction with blood coagulation
factor X (FX), which putatively ‘bridges’ the hexon protein in the
adenovirus capsid to heparan sulfate proteoglycans (HSPGs)
expressed on the surface of hepatocytes [17,20,21]. Ad5 utilises
the host FX protein, which circulates at approximately 8–10 mg/
ml in the bloodstream, for cell binding since the cell surface
interaction of the Ad5: FX complex is mediated through the serine
protease domain of FX and not through a direct interaction of the
virus with the cell surface [21]. This is of particular significance in
the context of disseminated adenoviral disease affecting immuno-
compromised patients, since typing studies have found a
predominance of species C adenoviruses in peripheral blood
samples from these individuals [6,22,23]. Interestingly, recent
surface plasmon resonance (SPR) studies have demonstrated that
of 22 Ad species tested, from species A, B, C and D, 14 can bind
FX [21] indicating that the interaction of Ad5 with FX may be
highly conserved. Only adenoviruses from species D lacked the
capacity to bind FX.
HSPGs are widely-expressed molecules composed of a core
protein to which one or more heparan sulfate (HS) glycosamino-
glycan (GAG) sidechains are covalently linked (reviewed in [24]).
Their core protein diversity, structural heterogeneity and high
negative charge (imparted by the HS-GAG sidechains, which
consist of highly-sulfated disaccharide repeats of N-acetylglucosa-
mine and glucuronic/iduronic acid) ensure that HSPGs play
important roles in many biological processes [25]. Furthermore,
several viral pathogens including the human immunodeficiency
virus-1 (HIV) [26], human papilloma virus (HPV) [27], adeno-
associated virus (AAV) [28] and herpes simplex virus (HSV) [29]
exploit HSPGs as primary attachment receptors in different tissues
and cell types. Although in vitro and in vivo studies suggest that the
Ad5:FX complex interacts with membrane HSPGs [17,30] the
specific receptor requirements underlying FX-mediated adenoviral
uptake have not been characterised. Interestingly, liver HS have
been shown to possess a specialised structure, with much higher
levels of N- and O-sulfation than HS from other tissues [31,32,33].
Viral interactions with HS sidechains at the cell surface are
frequently associated with the presentation of a particular
‘sulfation signature’ [34,35]. The substantial liver specificity of
systemically disseminating Ad5 may therefore be due to the
preferential interaction of Ad5:FX complexes with highly-sulfated
liver HS.
Here, we investigated the receptor requirements for FX-
mediated Ad5 cellular uptake in vitro and in vivo. We first showed
in a number of cell lines that the interaction of the Ad5:FX
complex with the cell surface was entirely independent of CAR
and av integrins. By analysing Ad5 binding and uptake into
enzymatically-pretreated cells we demonstrated that the primary
attachment of the Ad5: FX complex was specifically mediated by
HS sidechains. Detailed immunocytochemical analysis in vitro
revealed delayed FX-mediated cell entry and cytosolic transport to
the microtubule organising centre (MTOC) of a fluorescently-
labelled Ad5 mutant lacking the penton base RGD motif, showing
that rapid and efficient post-attachment kinetics is dependent on
engagement of av integrins. Chemical inhibition or genetic
ablation of endogenous HS sulfation completely abrogated FX-
mediated Ad attachment and cell uptake, indicating that the Ad5:
FX complex interacts with a specific HS sulfation pattern, while
heparin-mediated inhibition of adenoviral gene transfer in vitro and
Ad attachment to liver slices ex vivo was significantly attenuated in
the absence of heparin N- and, in particular, O-linked sulfate
groups. In vivo, Ad5 liver accumulation 1 h after intravenous
administration to mice was significantly and dose-dependently
inhibited by pre-inoculation with unmodified heparin but not by
de-sulfated heparins. Immunohistochemical analysis of liver
sections from mice intravenously injected with fluorescently-
labelled Ad5 revealed localisation of Ad particles in CD31+
hepatic sinusoids and surrounding hepatocytes. We have thus
integrated the established model of av integrin-dependent
adenoviral infection with the FX-mediated pathway leading to
liver uptake of Ad5.
Results
Heparan sulfate sidechains play an important role in FX-
mediated Ad5 cell uptake in vitro
We utilised Ad5CTL (vector based on wild type Ad5 capsid),
Ad5KO1 (CAR binding mutated), Ad5PD1 (integrin-binding
mutant) or Ad5KP (both mutations) – see Methods for details.
To assess the importance of HSPG heparan sulfate (HS) sidechains
in Ad5 cell binding and uptake mediated by interaction with
human FX we pre-treated human HepG2 hepatoma and SKOV3
ovarian carcinoma cells with heparinase III prior to performing
Ad5 cell attachment and gene transfer experiments in the presence
or absence of FX. Both HepG2 and SKOV3 cells express HSPGs,
however unlike HepG2 cells, SKOV3 cells express very low levels
of CAR [36]. Heparinase III is a heparin lyase that specifically
cleaves N-acetylated (NAc) and transition domains of HS and can
be used in vitro and in vivo to inhibit HS-mediated viral attachment
[27,37]. Cleavage of HS at NAc and transition domains was
assayed by FACS. Heparinase III digestion significantly and dose-
dependently reduced the percentage of cells positive for antibody
10E4, while significantly increasing the percentage of cells positive
Author Summary
Adenoviruses can infect many cell types and cause a range
of illnesses in humans, including respiratory, ocular and
gastrointestinal disorders. These illnesses are rarely fatal;
however, in immunocompromised individuals, especially
young children, disseminated adenovirus infections can
cause serious and life-threatening complications. Studies
have shown that several adenoviruses including vectors
based on adenovirus serotype 5 (Ad5) bind to coagulation
factor X (FX) in the bloodstream. Ad5 uses the high-affinity
interaction with FX to putatively bind to heparan sulfate
proteoglycans (HSPGs). However, very little is known about
this infection pathway. Here we demonstrate that interac-
tion of Ad5:FX with HSPGs is solely via the HS sidechains of
these ubiquitously-expressed molecules. We further show
that this interaction is dependent on HS sulfation, in
particular O-sulfation. Although attachment of Ad5:FX to
HSPGs is independent of the coxsackievirus and adenovi-
rus receptor (CAR) or av integrins, efficient and rapid
intracellular transport of Ad5 retains a dependence on
engagement of av integrins via the penton base protein.
This is the first study to characterise the receptor
requirements for cell uptake via the recently-identified,
FX-mediated infection pathway, which may be of signif-
icance for the development of therapies against dissem-
inated adenoviral disease.
Receptor Requirements for FX-Mediated Ad Infection
PLoS Pathogens | www.plospathogens.org 2 October 2010 | Volume 6 | Issue 10 | e1001142
for antibody 3G10, confirming the substrate activity of heparinase
III treatment (Fig. S1). To verify that heparinase III treatment had
no effect on the widely-expressed GAG chondroitin sulfate, which
is primarily composed of acetylgalactosamine hexosamine groups,
cell surface chondroitin sulfate was quantified by FACS using the
CS-56 mouse monoclonal antibody. While treatment of SKOV3
cells with chondroitinase ABC dose-dependently reduced the
percentage of CS-56 positive cells, heparinase III treatment had
no effect (Fig. S1), indicating that heparinase III treatment has no
effect on chondroitin sulfate. Ad5 attachment to cells was
substantially increased in the presence of FX in both HepG2
and SKOV3 cells (Fig. 1A and 1B; p,0.01). Similar results were
observed when Ad5 mutants ablated for CAR-binding and/or av
integrin binding (Ad5KO1, Ad5PD1 or Ad5KP; Fig. 1A) were
used, in agreement with previous studies showing that the FX-
mediated increase in virus cell attachment and gene transfer is
CAR- and av integrin- independent [17,30]. Similar FX-mediated
enhancement of virus uptake was also observed in a panel of
CARhigh and CARlow cell lines when Ad5CTL and the av integrin-
binding mutant Ad5PD1 were compared (Fig. S2). As expected
levels of FX-mediated enhancement in gene transfer were lower in
CARhigh cells compared to CARlow cells (Fig. S1) since the CAR
and FX pathways are both efficient in vitro pathways in the former.
The FX-mediated increase in virus cell attachment was signifi-
cantly attenuated by heparinase III pretreatment of HepG2
(p,0.01) or SKOV3 (p,0.05) cells (Fig. 1B). FX-mediated gene
transfer was also significantly decreased after heparinase III
pretreatment (Fig. 1C) of HepG2 and SKOV3 cells (p,0.01). We
next carried out virus transport experiments in vitro using an
Alexa488-labelled virus in the presence or absence of heparin.
Heparin and HS sidechains have very similar structures, although
heparin displays higher general sulfation than HS [25]. Heparin is
therefore frequently used as a competitive inhibitor for HS binding
[38,39]. In the absence of heparin, Ad5:FX complexes were
rapidly and efficiently transported to the MTOC in SKOV3 cells
within an hour of adding fluorescently-tagged Ad5CTL:FX
complexes to cells, as demonstrated by colocalisation with the
MTOC marker pericentrin (Fig. 1D, upper panel). In the presence
of heparin, however, FX-mediated attachment of fluorescently-
tagged Ad5CTL to the cell surface was completely abrogated
(Fig. 1D, lower panel), confirming that HS sidechains mediate
Ad5CTL:FX attachment to the cell surface. Similar results were
observed in SKOV3 and A549 human lung adenocarcinoma cells
(Fig. 1E). Taken together, these results indicate that FX-mediated
Ad5CTL cell attachment in vitro is dependent on the presence of
HS sidechains.
Optimal post-attachment cell entry and cytosolic
transport of Ad5 is dependent on an intact penton base
RGD motif
Although in vitro studies have shown that an intact penton base
RGD motif is required for efficient endosome escape after CAR-
mediated attachment of Ad5 to the cell surface [40] several in vivo
studies indicate that ablation of the penton base RGD motif does
not significantly affect liver uptake after systemic administration of
Ad5 [14,15,16,17,41]. Having established that FX-mediated
attachment of Ad5CTL to the cell surface requires HSPGs, we
next assessed the role of av integrins during FX-mediated Ad5 cell
uptake. In vitro cell tracking experiments were carried out in
CARlow SKOV3 [36] and CARhigh A549 cells [42] using Ad5
vectors with a mutated penton base RGD motif (Ad5PD1). Both
Ad5CTL and Ad5PD1 efficiently bound the cell membrane in the
presence of FX (Fig. 2A, B). In SKOV3 cells at 15 and 60 minutes
post-internalisation, both Ad5CTL and Ad5PD1 particles had
entered endosomal compartments as demonstrated by partial
colocalisation with the early endosomal marker EEA1 and Rab5
(Fig. 2A, B). Similar results were observed in A549 cells (data not
shown). MTOC colocalisation was quantified by assessing the
proportion of cells in a 406microscope field with colocalisation of
fluorescently-labelled Ad5 particles (green) with the MTOC
marker pericentrin (red; see upper panel in Fig. 3A, quantification
Fig. 3B–C). Cell entry and cytosolic transport kinetics of the CAR
binding-ablated vector Ad5KO1 closely resembled Ad5CTL,
confirming that FX-mediated cell uptake does not require CAR
(Fig. S3). Conversely, only 20–25% MTOC colocalisation was
observed for Ad5PD1 in SKOV3 and A549 cells at the same
timepoint (Fig. 3B and Fig. 3C, respectively). These data suggest
that an integrin-mediated post-internalisation signal is required for
optimal transport of Ad5CTL to the MTOC after FX-mediated
cell surface attachment of Ad5CTL to HSPGs. To confirm the
role of integrins we next performed a short hairpin (sh)RNA
approach to knockdown av integrin expression in SKOV3 cells
and assessed the effect of this on intracellular transport of
Ad5CTL. Target knockdown was confirmed using TaqMan and
flow cytometric analysis compared to mock-transfected and
scrambled control shRNA cells (Fig. 4A, B). Knockdown led to
a significant reduction in the localisation of Ad5CTL to the peri-
nuclear compartment (Fig. 4B–C) thus confirming the importance
of integrin engagement for transport via the FX-mediated
pathway. We next determined the effect of kinase inhibitors that
are known to affect cell entry and intracellular transport of
adenovirus [43]. We used H89 dihydrochloride (an inhibitor of
PKA), L Y294002 hydrochloride (an inhibitor of PI3K) and SB
203580 hydrochloride (an inhibitor of p38 MAPK). We observed
that co-incubation of Ad5CTL-transduced cells in the presence of
inhibitors of either PKA, PI3K or p38 MAPK was able to
significantly reduce Ad5CTL-mediated transport to the MTOC in
the presence of FX (Fig. S4). Since these molecules are linked to
activation of cellular integrins during Ad internalisation or
intracellular transport this further suggests that integrins are a
component of the viral entry cycle in the presence of FX.
Sulfation of HSPGs is critical for cell attachment and
uptake of Ad5:FX
Having established that FX-mediated Ad5CTL cell surface
attachment required HS sidechains, we next investigated whether
HS sidechain sulfation affects FX-mediated Ad5CTL cell uptake.
In vitro experiments were therefore carried out in HepG2 and
SKOV3 cells pretreated with increasing concentrations of sodium
chlorate, a selective inhibitor of sulfation [44]. We confirmed that
sodium chlorate treatment inhibited sulfation in a dose-dependent
manner (Fig. S5A), reduced binding of Ad5CTL to cells in the
presence of FX (Fig. S5B) in the absence of cellular toxicity (Fig.
S5C). Gene transfer was used as a marker of successful cellular
internalisation, cytosolic transport and nuclear uptake. FX-
mediated Ad5CTL gene transfer was inhibited in a dose-
dependent manner by pretreatment with sodium chlorate in both
HepG2 and SKOV3 cells (Fig. 5A), suggesting that FX-mediated
Ad5 uptake in vitro may depend on HS sidechain sulfation. No
effect on basal levels of Ad5CTL uptake was observed. To assess
the importance of HS sulfation for FX-mediated Ad5CTL
transduction, cell attachment and transduction assays were carried
out in CHO cell lines deficient in HS biosynthesis enzymes.
Although FX induced a 60-fold increase in Ad5 cell attachment
and uptake in parental CHO-K1 (CAR-) cells, no FX-mediated
increase was observed in CHO-pgsA745 cells, which do not
express xylosyltransferase-1 (XT1) and are consequently defective
in HS-GAG synthesis [45] (Fig. 5B–C). The FX-mediated increase
Receptor Requirements for FX-Mediated Ad Infection
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in Ad5 cell attachment and transduction was also significantly
attenuated in N-deacetylase/N-sulfotransferase-1 (NDST1)-defi-
cient CHO-pgsE606 cells, which synthesise HS chains with
significantly reduced O- and, in particular, N sulfate groups [46]
(Fig. 5B–C). Interestingly, FX was unable to increase Ad5CTL cell
attachment and uptake in CHO-pgsF17 cells, which are 2-O-
sulfotransferase-deficient and therefore lack 2-O-sulfated residues
[47] (Fig. 5B–C). Similar results were obtained in all cell lines
using the av integrin-binding mutant AdPD1 (Fig. 5B and 5C).
Taken together, these data suggest that attachment of the
Ad5CTL:FX complex to cell surface HSPGs in vitro requires HS
sidechain sulfation.
Removal of sulfate groups attenuates the ability of
heparin to inhibit Ad5:FX binding and cellular uptake in
vitro and ex vivo
To confirm the importance of HS sidechain sulfation for FX-
mediated Ad5CTL cell attachment and uptake, in vitro gene
transfer and ex vivo attachment experiments were carried out in the
presence of heparan sulfates or heparins with biosynthetically-
modified sulfation. Bovine intestinal heparin and porcine intestinal
heparan sulfate are very highly-sulfated [39]. In contrast, porcine
kidney heparan sulfate possesses fewer N- and O- sulfate groups,
while de-N-sulfated heparin lacks N-sulfated glucosamine residues
[39] and de-O-sulfated heparin lacks O-sulfate groups [39,48].
Competitive inhibition experiments in vitro and ex vivo were carried
out in SKOV3 cells or mouse liver slices, respectively, in the
presence or absence of FX.
Dose-dependent inhibition of FX-enhanced Ad5CTL gene
transfer into SKOV3 cells was observed in the presence of all
heparins and heparan sulfates (Fig. 6A). However the IC50 values
for the highly-sulfated bovine intestinal heparin and porcine
intestinal heparan sulfate (5.1 mg/ml and 5.2 mg/ml respectively)
were lower than the IC50 values for the de-sulfated heparins
(39.1 mg/ml and 73.4 mg/ml for de-N-sulfated or de-O-sulfated
heparins respectively) or heparan sulfate with reduced sulfation
(porcine kidney heparan sulfate, 17.7 mg/ml) (Fig. 6A). Similar
results were obtained when CAR- or av integrin binding-ablated
viruses were used (Table S1).
Next, the attachment of fluorescently-labelled Ad5CTL (green)
to mouse liver slices ex vivo was analysed. Adherent Ad5CTL
particles were quantified by analysing captured images of 606
microscope fields using the ImageJ automated cell counting
function. Co-incubation with FX significantly increased the
attachment of fluorescently-labelled Ad5CTL to liver sections
(Fig. 6B and Fig. 5C). At the concentrations used, heparin
significantly inhibited FX-mediated attachment of Ad5CTL to
liver sections (p,0.01; Fig. 6B–C). However neither de-O-sulfated
nor de-N-sulfated heparin inhibited the attachment of Ad5CTL to
liver sections in the presence of FX. These results indicate that
binding of the Ad5CTL-FX complex to heparin/HS in vitro
requires the presence of highly anionic sulfate groups, supporting
the hypothesis that FX-mediated Ad5CTL cell uptake is
dependent on HS sidechain sulfation.
Inhibition of Ad liver accumulation in vivo by heparin is
sulfation-dependent
To identify whether the sulfation status of hepatocyte HS
contributes to the liver uptake of Ad5CTL from the circulation,
competitive inhibition experiments were carried out in vivo in the
presence of heparins with biosynthetically-modified sulfation. Mice
were inoculated with increasing concentrations of heparins prior to
intravascular administration of Ad5CTL. Ad5CTL liver uptake at
an early timepoint post-inoculation was then quantified by assessing
viral genome accumulation 1 h post-administration. Cellular
localisation of Ad5CTL in mouse livers was analysed by staining
liver sections with CD31 to visualise the vasculature in conjunction
with fluorescently labelled Ad5CTL. We have previously shown
that the FX-pathway is hepatocyte-specific and Kupffer cell uptake
is unaffected by pharmacological modulation or genetic approaches
to modify FX binding as Kupffer cell uptake is a scavenging process
[49,50,51,52]. We therefore used macrophage-depleted mice to
allow selective visualisation of HSPG uptake mechanisms via the
FX pathway in vivo at an early time point post injection.
Heparin pre-inoculation at both 20 mg/kg and 50 mg/kg
significantly and dose-dependently inhibited Ad5CTL accumula-
tion in the liver 1 h post-inoculation (p,0.01)(Fig. 7A). Although no
effect was observed at either dose of de-O-sulfated heparin (20 mg/
kg or 50 mg/kg), significantly fewer Ad5CTL genomes were
detected in livers of mice pre-treated with 50 mg/kg de-N-sulfated
heparin (p,0.05)(Fig. 7A). Immunofluorescence staining for CD31
was performed to facilitate identification of endothelial sinusoids in
the liver architecture. Sections from control mice inoculated with
fluorescently-labelled Ad5CTL (green) showed accumulation of
Ad5CTL particles in liver sinusoids and on the surface of
hepatocytes (Fig. 7B, upper panel). Administration of heparin (both
20 mg/kg and 50 mg/kg doses) or high-dose de-N-sulfated heparin
clearly reduced accumulation of labelled Ad5 while de-O-sulfated
heparin had no effect at either dose (Fig. 7B, lower panel).
Taken together, our data indicate that the hepatic uptake
observed after intravenous administration of Ad5CTL is depen-
dent on HS sidechain sulfation, with a particular requirement for
O-sulfation. In conjunction with previous studies showing that liver
HS is highly enriched in 2-O-sulfated residues [31] our in vitro, ex
vivo and in vivo results further suggest that the hepatic tropism of
Ad5CTL may be due to preferential binding of the Ad5:FX
complex to HS sidechains.
Discussion
Previous studies have shown that the liver uptake of Ad5 after
exposure to the circulation is dependent on FX binding directly to
Figure 1. Importance of HS sidechains during Ad5 binding, cell entry, cytosolic transport and transduction in vitro. (A) Binding of 1000
vp/cell Ad5CTL, Ad5KO1(CAR-binding mutant), Ad5PD1 (av integrin-binding mutant) or Ad5KP(CAR- and av integrin-binding mutant) particles to cells
was quantified after incubation of Ad particles with HepG2 or SKOV3 cells for 1 h at 4uC in the presence or absence of 10 mg/ml FX. Vector genomes
were detected by quantitative PCR. (B+C) SKOV3 (left panels) or HepG2 (right panels) cells were incubated for 1 hour at 37uC in serum free media
containing 0–5 U/ml of Heparinase III. The effect of heparinase pre-treatment on FX-mediated Ad5 binding (1000 vp/cell, 1 hour, 4uC) (B) or Ad5
mediated transduction (1000 vp/cell, 3 hours, 37uC) was quantified (C). ** = p,0.01. (D) (upper panel) 10,000 vp/cell of Alexa488-labelled Ad5
(green) were allowed to bind cells for 1 h at 4uC, then incubated at 37uC for 60 min prior to fixation and staining for the MTOC marker pericentrin
(red). Nuclei were counterstained using DAPI. Colocalisation of fluorescently-labelled Ad5 particles with pericentrin is indicated by the yellow arrows.
Images were captured on a confocal microscope under a 636objective (D) (lower panel) Alexa-labelled Ad5 was allowed to bind cells for 1 h at 4uC
in the presence or absence of 10 mg/ml FX and/or heparin (Hep). Cells were then incubated at 37uC for 0 min to 60 min prior to fixation. Nuclei were
counterstained using DAPI. (E) Fluorescently-labelled Ad5 was allowed to bind cells for 1 h at 4uC in the presence or absence of 10 mg/ml FX and
heparin (Hep). Nuclei were counterstained using DAPI. Images were captured under a 406objective.
doi:10.1371/journal.ppat.1001142.g001
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the hexon protein in the Ad5 capsid, putatively via a FX-mediated
interaction with hepatocyte membrane HSPGs [17,30]. In the
present study we investigated the functional receptor requirements
for the Ad5CTL:FX complex using a variety of in vitro, ex vivo and
in vivo experimental approaches.
We have demonstrated that FX-mediated Ad5CTL cell
attachment in vitro requires the presence of HS sidechains but
not CAR or av integrins. FX-mediated Ad5CTL binding to
CARhigh HepG2 and CARlow SKOV3 cells was not affected by
fiber knob or penton base mutations ablating CAR- or av integrin-
interacting motifs, respectively, indicating that neither CAR nor av
integrins were required for the FX-mediated primary interaction
with the cell surface. Conversely, cleavage of HS sidechains by
heparinase III pretreatment significantly inhibited FX-mediated
Ad5 attachment to and uptake into HepG2 and SKOV3 cells.
Heparin, a highly-sulfated HS analogue, also abrogated FX-
mediated adenoviral cell surface binding. Moreover, no FX-
mediated enhancement of Ad5CTL cell binding or gene transfer
was observed in CHO-pgsA745 cells which do not display HS
sidechains. Taken together, these results clearly demonstrate that
Figure 2. Endosomal localisation of av integrin binding-defective Ad5 in vitro. (A+B) 10,000 vp/cell of Alexa488-labelled Ad5CTL or Ad5PD1
(green particles) in the presence of FX were allowed to bind cells for 1 h at 4uC, then incubated at 37uC for increasing lengths of time (15 min,
60 min) to allow internalisation and trafficking prior to fixation and staining for the early endosome markers EEA1 (A) or Rab5 (B). Specific binding of
primary antibodies against EEA1 (A, upper panel) or Rab5 (B, upper panel) was detected using a Alexa546-labelled secondary antibody (red).
Nuclei were counterstained using DAPI. Images were captured on a confocal microscope under a 636objective.
doi:10.1371/journal.ppat.1001142.g002
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the primary interaction of the Ad5CTL:FX complex with the cell
surface is mediated via HS sidechains. Although our data indicate
that CAR- or av integrins are not required for FX-mediated
attachment of Ad5CTL to the cell surface, intracellular transport
experiments using a mutant with an ablated penton base RGD
motif (Ad5PD1) and a knockdown shRNA approach revealed that
efficient and rapid post-internalisation transport of virus particles
to the nucleus requires engagement of RGD-interacting integrins.
A similar delay in intracellular transport of Ad5PD1 was observed
in CARhigh A549 and CARlow SKOV3 cells, suggesting that the
altered transport was not affected by differences in CAR
expression. Interestingly, a previous study investigating the
cytoplasmic transport of Ad5 after CAR-mediated cell surface
attachment has demonstrated a similar reliance on RGD-integrin
interactions [40]. In conjunction with this study, our results
indicate that integrin engagement is required for rapid and
efficient intracellular transport of Ad5CTL regardless of the
primary attachment receptor used. Furthermore, the potential HS
sidechain dependence of FX-mediated cell surface attachment
suggests that the Ad5CTL:FX complex may utilise HSPGs as
attachment factors in a similar manner to other hepatotropic
viruses such as HSV [53] hepatitis [34,54] and AAV-2 [55,56].
A central aim of the present study was to establish whether FX-
mediated Ad5CTL cell uptake is dependent on the degree or type
of HS sidechain sulfation. Blocking HS sulfation by pre-incubating
cells with increasing concentrations of sodium chlorate dose-
Figure 3. Delayed FX-mediated transport of av integrin binding-defective Ad5 in vitro. 10,000 vp/cell of Alexa488-labelled Ad5CTL or
Ad5PD1 (green particles) in the presence of FX were allowed to bind cells for 1 h at 4uC, then incubated at 37uC for increasing lengths of time
(15 min, 60 min, 180 min) to allow internalisation and transport prior to fixation and staining for the MTOC marker pericentrin (A). Specific binding of
a primary antibody against pericentrin (A, upper panel) was detected using an Alexa546-labelled secondary antibody (red). Nuclei were
counterstained using DAPI. Images were captured on a confocal microscope under a 636objective. (B+C) Percentage of cells with colocalisation of
fluorescently-labelled Ad5CTL or Ad5PD1 with the MTOC marker pericentrin in SKOV3 (B) or A549 cells (C) was calculated by analysing at least 5
separate 406microscope fields per experimental condition. ** = p,0.01 compared to Ad5CTL values, error bars represent S.E.M.
doi:10.1371/journal.ppat.1001142.g003
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Figure 4. Effect of shRNA depletion of av integrin on FX mediated Ad5 transport. Knockdown of av integrin mRNA and protein expression
levels in SKOV3 cells was quantified by qPCR (A) and flow cytometry (B), respectively. The effect of shRNA depletion on Ad5 trafficking in SKOV3 cells
was assessed as previously. Representative images are shown (B) and quantification of peri-nuclear Ad5CTL localisation was calculated by analysis of
5 separate microscope fields per experimental condition (C). **p,0.05 vs both control conditions. (D) Percentage of SKOV3 cells with colocalisation
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dependently inhibited FX-mediated Ad5CTL gene transfer in
HepG2 and SKOV3 cells. Moreover, FX-mediated enhancement
of Ad5CTL cell attachment and uptake was significantly
attenuated in CHO-pgsE606 cells, which have reduced overall
sulfation due to a deficiency in the N-deacetylase/N-sulfotransfer-
ase-1(NDST1) gene [46]. In addition, IC50 values for porcine
kidney heparan sulfate, which possesses fewer sulfate groups than
heparin, were approximately 3-fold higher than IC50 values for
highly-sulfated bovine intestinal heparin or porcine intestinal
heparan sulfate. These data show that FX-mediated Ad5 cell
attachment and uptake is dependent on the degree of HS
sidechain sulfation. Interestingly, removal of N- or O- sulfate
groups significantly attenuated the inhibitory capabilities of
heparin on Ad5CTL uptake in vitro, increasing IC50 values
approximately 8- or 14-fold respectively. Furthermore, unlike
native heparin, de-O-sulfated and de-N-sulfated heparins were
unable to inhibit FX-mediated attachment of fluorescently-
labelled Ad5CTL to liver slices ex vivo. Finally, no FX-mediated
enhancement of Ad5CTL cell attachment or uptake was observed
in CHO-pgsF17 cells, which lack 2-O-sulfate groups due to a
deficiency in the 2-O-sulfotransferase gene [47]. Taken together,
our results suggest that while the degree of sulfation modulates the
FX-mediated uptake of Ad5CTL in vitro, the Ad5CTL:FX
complex may also preferentially interact with specific sulfate
moieties.
A number of previous studies have examined the biochemical
composition of heparan sulfate from different tissues and have
shown that liver heparan sulfate is enriched in sulfated moieties, in
particular 2-O sulfate groups [31,33]. Interestingly, hepatic
clearance of intravenously-administered very low density lipopro-
tein (VLDL) is significantly reduced in mice with liver-specific
knockout of the heparan sulfate 2-O sulfotransferase enzyme [57],
thereby adding mechanistic insight into previously published work
documenting increased levels of systemic VLDL in mice with
reduced overall liver HS sulfation [32]. These studies show that
the specialised structure of liver HS can contribute to the hepatic
accumulation and uptake of circulating particles, and indicate how
liver HS sulfation may contribute to the accumulation of
systemically-disseminated, FX-interacting adenoviruses such as
Ad5. The final aim of this study was therefore to investigate the
importance of HS sidechain sulfation in FX-mediated Ad5CTL
interactions with liver cells in vivo. While pre-injection of native
heparin or high-dose de-N-sulfated heparin significantly attenuat-
ed Ad5CTL genome accumulation in the livers of macrophage-
depleted mice 1 h after intravenous delivery, administration of de-
O-sulfated or low-dose de-N-sulfated heparin had no effect.
Immunohistochemical analysis of fluorescently-labelled Ad5CTL
in liver sections from these mice clearly showed a significant
reduction in Ad5CTL accumulation around CD31+ hepatic
sinusoids after pre-injection of high-dose native and de-N-sulfated
heparin, but not de-O-sulfated heparin. These results are
consistent with our in vitro and ex vivo data, suggesting that HS
sidechain sulfation (in particular O-sulfation) may contribute to the
accumulation of Ad5CTL in the liver at this timepoint after
intravenous administration. Taken together, our data indicate that
the FX-mediated interaction of Ad5CTL with HSPGs both in vitro
and after intravascular administration in vivo involves the
presentation of a ‘sulfation signature’.
The domains of FX responsible for mediating Ad5 transduction
of hepatocytes have been demonstrated. The Gla domain of FX
docks in the cup at the centre of each hexon trimer and the
virus:FX complex is then delivered to the hepatocyte surface via a
heparin binding exosite in the FX serine protease domain which
tethers to HSPGs at the cell surface [21]. While activated FX
(FXa) has previously been shown to bind to the cell surface of
hepatocytes and tumour cell lines, this interaction was not
observed with FX [58]. The cell surface receptors that mediate
FXa interactions with hepatocytes were later shown to be tissue
factor pathway inhibitor and nexin-1 and required a functional
FXa active site [59]. Previously, it was also shown that a Ca2+-
mediated interaction between the Gla domain of FX and
phospholipid components of the cell membrane mediated cell
surface interactions [60,61]. A similar phospholipid-mediated
interaction between FX and platelets has also been reported
[62]. FX has also been previously shown to mediate interactions
with the cell membrane of other cell types via other identified
receptors. For example, in whole human blood FX has been
shown to bind monocytes via the aMb2 integrin (CD11b/CD18),
resulting in its activation via cathepsin G-mediated cleavage,
although the domain of FX that binds CD11b was not identified
[63].
Previous studies have shown that binding of Ad3 fiber knob to
HSPGs in vitro is also dependent on HS sidechain sulfation [64]. A
putative HSPG-binding region has been identified in the Ad5 fiber
shaft (91KKTK94) [41]. However while reduced hepatic uptake
was observed after intravascular administration of a virus
harbouring a mutation of the KKTK motif (91KKTK94RGAGA),
in vitro assays showed that this virus was deficient in intracellular
transport [65]. A recent study has clearly demonstrated that fiber
is not involved in binding of the Ad5:FX complex to the cell
surface, since a fiberless Ad5 mutant showed no significant
reduction in FX-mediated cell surface attachment [21]. This study
also showed that the Gla domain of FX binds to hypervariable
regions in the Ad5 hexon [21], while positively-charged residues in
the FX serine protease domain putatively interact with HSPGs
[21,66,67,68]. It is therefore likely that the HS sidechain-
dependent interaction of Ad5 with the cell surface is mediated
by FX ‘bridging’ to hexon capsid proteins rather than by a direct
interaction with fiber.
In the past two decades there has been significant interest in the
potential use of sulfated polysaccharides such as heparin and
heparan sulfates in antiviral therapy (reviewed in [69]). For
example, the polyanionic compound PRO 2000 competitively
inhibits attachment of the HIV-1 envelope protein gp120 to
HSPGs on CD4+ T cells and is currently under development as a
topical antiviral gel to prevent cervical HIV-1 transmission
[70,71]. However undesirable side-effects such as anticoagulation
limit the use of certain highly-sulfated, high molecular weight
polysaccharides, including heparin. As stated previously, viral
interactions with HS sidechains at the cell surface are often
associated with the presentation of a particular ‘sulfation
signature’. For instance, hepatitis E cell binding is thought to be
dependent on 6-O sulfation [34] while the interaction of HSV-1
with the surface of target cells during infection in vivo is mediated
by 3-O sulfate moieties [35]. Knowledge of the specific positioning
and number of sulfate groups required for optimal virucidal
activity has facilitated the development of targeted antiviral
polyanions such as carrageenan and cellulose sulfate, which have
significantly fewer side-effects [69]. This underlines the therapeutic
relevance of fully understanding the sulfation requirements for
of fluorescently-labelled Ad5CTL in the perinuclear region was calculated by analysing at least 5 separate 406microscope fields per experimental
condition. ** = p,0.01 compared to off target shRNA values, error bars represent S.E.M.
doi:10.1371/journal.ppat.1001142.g004
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Figure 5. Importance of HSPG sulfation for FX-mediated Ad transduction in vitro. (A) HepG2 or SKOV3 cells that had been pretreated with
increasing concentrations of the sulfation inhibitor sodium chlorate were transduced with 1000 vp/cell of Ad5CTL in the presence (closed bars) or
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Ad5:FX attachment to host cell HSPGs. This is of particular
importance in the context of disseminated adenoviral disease in
immunocompromised patients, as several studies have identified
FX-binding species C adenoviruses in peripheral blood samples
from these individuals [6,7,8,9]. Further detailed studies on the
receptor-mediated interactions of Ad5 in circulation are now
required to fully characterise the factors underlying the clinical
pathogenicity of this virus.
Materials and Methods
Ethics statement
All animal experiments were approved by the University of
Glasgow Animal Procedures and Ethics Committee and per-
formed under UK Home Office licence (PPL 60/3752) in strict
accordance with UK Home Office guidelines.
Materials
Purified human blood coagulation factor X (FX) was purchased
from Cambridge Biosciences (Cambridge, UK). Heparinase III,
chondroitinase ABC, bovine intestinal heparin, porcine intestinal
heparan sulfate, porcine kidney heparan sulfate, de-N-sulfated
heparin, de-O-sulfated heparin and sodium chlorate were
obtained from Sigma (Sigma-Aldrich, Gillingham, UK). Primary
antibodies raised against EEA1, Rab5, pericentrin or a-tubulin
were obtained from Abcam (Cambridge, UK). Primary antibodies
raised against intact heparan sulfate (clone 10E4) or heparinase
III-digested heparan sulphate (clone 3G10) were obtained from
AMS Biotechnology (Oxford, UK). The primary antibody raised
against chondroitin sulfate (clone CS-56) was obtained from Sigma
(Sigma-Aldrich, Gillingham, UK). All secondary antibodies were
obtained from Invitrogen (Paisley, Scotland, UK). The kinase
inhibitors LY 294002 hydrochloride, H 89 hydrochloride and SB
202190 hydrochloride were obtained from Tocris Bioscience
(Bristol, UK).
Cell lines, cell culture and virus production
A549 (human lung carcinoma ATCC CCL-185), HT29 (human
colorectal adenocarcinoma: ATCC HTB-38), MDA-MB-231
(human breast adenocarcinoma: ATCC HTB-26) NCI-H522
(human lung adenocarcinoma: ATCC CRL-5810), SKOV3
(human ovarian carcinoma: ATCC HTB-77) and SNB19 cells
(human glioblastoma: ATCC CRL-2219) were grown in RPMI
1640 medium supplemented with 10% fetal calf serum, 2 mM L-
glutamine and 1% penicillin-streptomycin (Invitrogen, Paisley,
UK). HepG2 (human hepatocellular carcinoma: ATCC CRL-
11997) and 293 (Human Embryonic Kidney: ATCC CRL-1573)
cells were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM; Invitrogen, Paisley, UK) supplemented with 10% fetal
calf serum, 2 mM L-glutamine and 1% penicillin-streptomycin.
CHO-pgsA745 (ATCC: CRL-2242), CHO-pgsE606 (ATCC:
CRL-2246) and CHO-pgsF17 cells [47] were grown in Ham’s
F-12 medium (Invitrogen, Paisley, UK) supplemented with 10%
fetal calf serum, 2 mM L-glutamine and 1% penicillin-streptomy-
cin. The E1/E3-deleted Ad5CTL adenovirus encodes a Rous
sarcoma virus (RSV) promoter-driven LacZ expression cassette as
described previously [66]. Ad5KO1 is based on Ad5CTL and
contains a two-amino acid substitution in the fiber knob (S408E,
P409A) that ablates CAR binding. Ad5PD1 is also based on Ad5
and contains a substitution of amino acids 337–344 of the penton
base gene (HAIRGDTF) with amino acids SRGYPYDVP-
DYAGTS, ablating RGD-mediated av integrin-binding. Ad5KP
contains both fiber knob (KO1) and penton base (PD1) mutations.
Viruses were propagated in 293 cells and purified by CsCl
gradient centrifugation. Vector genomes were quantified by SYBR
green quantitative polymerase reaction (qPCR) on an Applied
Biosystems ABI Prism 7700 sequence detection system using
primers directed against the LacZ transgene (forward 59-
ATCTGACCACCAGCGAAATGG-39 and reverse 59-CAT-
CAGCAGGTGTATCTGCCG-39). Viral particles were deter-
mined by micro bicinchoninic-acid assay (Perbio Science,
Cramlington, UK) using the formula 1 mg protein = 46109 VP
[72].
Virus labelling
Adenoviruses were fluorescently labelled using an Alexa Fluor-
488 (green) protein labelling kit according to the manufacturer’s
instructions (Invitrogen, Paisley, UK). Free label was dialysed from
labelled Ad5 using 10,000 molecular weight cut off slide-a-lyzer
cassettes (Perbio Science, Cramlington, UK) overnight in 100 mM
Tris, 50 mM EDTA. A dye: virus particle ratio of 3:1 was used for
all labelling reactions. Fluorescent dye labelling efficiency was
assessed using the ‘proteins and labels’ function on a Nanodrop-
1000 spectrophotometer. Infectivity of labelled adenoviruses was
verified by in vitro gene transfer assay as described below.
Flow cytometric analysis of heparinase III pretreatment
FACS was performed on SKOV3 cells cultured under the
conditions described above. Cells were detached from culture
vessels using a 16 citric saline solution and counted using trypan
blue exclusion. Cells were then resuspended in serum-free DMEM
(SFDMEM) at a concentration of 46106 cells/ml. Heparinase III
or chondroitinase ABC was then added to 50 ml of this cell
suspension at the required concentrations (0 U/ml, 0.5 U/ml,
1 U/ml, 5 U/ml) and incubated with cells in a shaking waterbath
at 37uC for 1 h. Cells were washed twice in SFDMEM) then
incubated with primary antibodies (10E4, 3G10 or CS-56; all
mouse monoclonal antibodies) or a matching isotype control in
SFDMEM containing 0.1% BSA for 30 min on ice. Cells were
then washed twice and incubated with a FITC-labelled secondary
antibody in SFDMEM for 30 minutes on ice. Cells were washed
twice and cell labelling was then detected on a FACS Canto II
flow cytometer (Beckton Dickinson, Oxford, UK) using FACS
DIVA software. Viable cells were gated by their FSC/SSC
profiles, with a minimum of 5000 gated events analysed per
sample. Results are expressed as percentage positively-stained cells
per sample, from 3 independent samples analysed in triplicate.
Measurement of sulfated glycosaminoglycan (sGAG)
content
Total sulfated glycan content was measured in cell lysates using
the Blyscan sulfated GAG assay kit (Biocolour, Newtonabbey,
absence (open bars) of 10 mg/ml FX. Pretreated cells were incubated with virus for 3 h at 37uC. Reporter gene activity was quantified 48 h post-
transduction. * p,0.05, **p,0.01 compared to control values (0 mM). (B+C) Control CHO-K1, HS-deficient CHO-pgsA745, sulfation-low CHO-pgsE606
or 2-O-sulfation-deficient CHO-pgsF17 were transduced with 1000 vp/cell of Ad5CTL or Ad5PD1 in the presence or absence of 10 mg/ml FX. (B) Cell
binding of Ad particles was quantified after incubation for 1 h at 4uC. Vector genomes were detected by quantitative PCR as described previously. (C)
Ad5CTL or Ad5PD1 was incubated with cells for 3 h at 37uC. Reporter gene activity was quantified 48 hours post-infection. * p,0.05, **p,0.01
compared to -FX values.
doi:10.1371/journal.ppat.1001142.g005
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Figure 6. The inhibitory effects of heparin on FX-Ad uptake in vitro and ex vivo are sulfation-dependent. (A) SKOV3 cells were
transduced with 1000 vp/cell of Ad5 in the presence or absence of 10 mg/ml FX and varying concentrations of heparins/heparan sulfates for 3 h at
37uC. Reporter gene expression was quantified 48 h post-transduction. IC50 (mg/ml, inset) values were calculated using the Hill-Slope model. *p,0.05,
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Northern Ireland, UK) according to manufacturer’s instructions.
Briefly, cultured cells were lysed in RIPA buffer (50 mM Tris,
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40)
then lysates were incubated with a molar excess of the cationic,
sulfate-binding dye 1,9 dimethylmethylene blue. Lysates were
pelleted and unbound dye was removed. Soluble GAG content
was measured by determining the quantity of bound dye by
spectrophotometric standard curve analysis at 656 nm. Protein
concentrations were measured by Bicinchoninic Acid Assay
(Perbio Science, Cramlington, UK) as described above. Data are
expressed as mg sGAG/mg protein.
Analysis of Ad5 transport in vitro
Cells were seeded in 4-well chamber slides at 16105 cells/well
24 h prior to assay. Cells were gently washed with PBS then
incubated with 16104 vp/cell in 300 ml SFDMEM for 1 h on ice.
Factor X and bovine intestinal heparin were both used at a
concentration of 10 mg/ml. Cells were then gently washed with
PBS and incubated at 37uC for 15, 30, 60 or 180 minutes prior to
fixation. Localisation of Ad particles at the MTOC was
characterised by staining cells using a polyclonal rabbit pericentrin
antibody (1:200 dilution: Abcam, Cambridge, UK) while localisa-
tion of Ad particles in early endosomes was characterised by
staining cells using a polyclonal rabbit EEA1 antibody (Early
Endosome Antigen-1) or a polyclonal rabbit Rab5 antibody at a
1:200 dilution (Abcam, Cambridge, UK). Cell morphology was
assessed using a polyclonal mouse a-tubulin antibody at a 1:500
dilution (Abcam, Cambridge, UK). Specific binding of primary
antibodies was visualised using a goat anti-rat Alexa Fluor 546
(red) secondary antibody in PBS at a dilution of 1:500. Cells were
imaged using a Zeiss confocal imaging system (LSM500).
Colocalisation of Ad5 with the MTOC was quantified by visually
assessing the percentage of cells with Alexa488-virus and
pericentrin co-staining. Data were averaged from 5 406
microscope fields per experimental condition.
Analysis of Ad5 trafficking in vitro in the presence of
kinase inhibitors
Cells were seeded in 8-well chamber slides at 56104 cells/well
24 h prior to assay. Cells were gently washed with PBS then
incubated with 100 mM LY 294002 hydrochloride, 40 mM H 89
hydrochloride or 10 mM SB 202190 hydrochloride (Tocris
Bioscience, UK) for 30 minutes at 37uC. Cells were gently washed
with PBS then incubated with 16104 vp/cell of Alexa Fluor-488
labelled virus in the presence of 100 mM LY 294002 hydrochlo-
ride, 40 mM H 89 hydrochloride or 10 mM SB 202190
hydrochloride in 150 ml SFDMEM for 1 h on ice. Factor X was
used at a concentration of 10 mg/ml. Cells were incubated at 37uC
for 180 minutes prior to fixation. Localisation of Ad particles at
the MTOC was characterised and quantified as previously
described.
Analysis of shRNA mediated depletion of cellular av
integrins and effect on FX mediated Ad5 trafficking
To evaluate the effect of depletion of cellular av integrins on FX
mediated Ad5 trafficking, SKOV3 cells (56104 cells/well in either
24 well plates or 8 well chamber slides) were transfected with
shRNA targeting av integrin, ‘‘off-target’’ control shRNA, or
liposomes only (mock transfected), according to manufacturer’s
instructions. Briefly, 2.5 ml/well of 5 mM shRNA was diluted 50 ml
in serum free media before being mixed with 50 ml/well of
SFDMEM containing 2 ml Dharmafect transfection reagent. The
lipid and shRNA solution were mixed and allowed to stand at
room temperature for 30 minutes before the addition of 400 ml/
well of complete media. Cells were washed with PBS and 500 ml/
well of lipid/shRNA solution was added and allowed to transfect
cells for 24 hours prior to analysis of knockdown. We confirmed
specific knockdown of av integrin by detection of av integrin
mRNA by RT-qPCR and by flow cytometry for surface levels of
the av subunit. Total cellular mRNA was harvested using RNeasy
mini kit (Qiagen), quantified, and 300 ng of mRNA was converted
to cDNA by in vitro reverse transcription. Levels of av integrin
mRNA in 2.5 ml of cDNA were subsequently quantified by
TAQman qPCR and normalised to total levels of the housekeeper
GAPDH. For analysis of av integrin knockdown by flow
cytometry, cells were detached 48 h post-transfection and
incubated with an anti-av antibody (mAb mouse IgG1 clone
L230) for 1 h at 4uC at a final concentration of 10 mg/ml. Cells
were washed with SFDMEM, incubated with goat anti-mouse
Alexa488-secondary (1:125 dilution) for a further hour at 4uC,
washed again with SFDMEM and resuspended in a final volume
of 350ml. Surface levels of the av integrin subunit were detected
using a BD FACS CANTO II flow cytometer, acquiring .10,000
gated events. For cell transport studies, cells were transfected as
above in 8-well chamber slides for 24 hours. Cells were
subsequently washed and cooled to 4uC, before the addition of
fluorescently labelled Ad5 (10,000 vp/cell) in serum free media
containing physiological levels of FX. Cells were then placed at
37uC for the stated times, washed, fixed using 4% paraformalde-
hyde in PBS for 10 minutes before counterstaining with 49,6-
diamidino-2-phenylindole (DAPI) and mounting in Prolong Gold
for analysis as previously described.
Analysis of Ad5 attachment ex vivo
Six mm frozen liver sections from macrophage-depleted male
MF1 mice were incubated with 16109 vp of Alexa488-labelled
Ad5CTL in SFDMEM in the presence or absence of 10 mg/ml
FX and/or increasing concentrations of heparins for 1 h on ice.
Sections were then washed twice with PBS and mounted using
ProLong Gold antifade reagent with DAPI. Sections were imaged
using an Olympus Cell‘M imaging system. To quantify adherent
Alexa488-Ad5CTL particles, 406 images captured using an
Olympus imaging system and were processed using PaintShop
Pro and ImageJ. Viral particles were counted using the semi-
automated cell counting tool from ImageJ. An average of 5
captured images were analysed per experimental condition.
In vivo assessment of Ad5 uptake
All animal experiments were approved by the UK Home
Office. Male MF1 outbred mice aged between 8–10 weeks (weight
approximately 35g) and housed in secure barrier facilities were
used for all in vivo experiments. Macrophage depletion was carried
out by clodronate liposome pretreatment as described previously
[21,66]. Kupffer cell depletion was confirmed by staining frozen
**p,0.01 compared to CON+FX (i.e. no heparin) values. (B) Liver slices from MF1 mice were incubated with 16108 vp of Alexa488-labelled Ad5CTL
(green) in the presence or absence of 10 mg/ml FX and increasing concentrations of heparins for 1 h at 4uC. Nuclei were counterstained using DAPI.
Images were captured using a 606 microscope objective. (C) Attachment of Alexa488-labelled Ad5CTL particles to mouse liver slices were
quantitated using the automated cell counting function in ImageJ. Data represent the average number of particles per 606 microscope field.
#p,0.01 vs FX2 conditions, ** = p,0.01 vs FX+ conditions in the absence of heparin.
doi:10.1371/journal.ppat.1001142.g006
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Figure 7. Effect of modified heparins on Ad5 liver accumulation. (A) Heparin or modified heparins were administered to macrophage-
depleted MF1 mice 5 minutes prior to intravenous injection of 161011 vp of Ad5. Mice were sacrificed 1 h later and Ad genomes were detected in
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liver sections with a rat anti-mouse F4/80 primary antibody at a
1:50 dilution (Abcam, Cambridge, UK) and a goat anti-rat Alexa
Fluor 546 (red) secondary antibody at a 1:500 dilution and all
sections in macrophage depleted mice showed a complete absence
of Kupffer cells to confirm the efficiency of depletion (data not
shown). For the analysis of virus genome accumulation in the liver
1 h after intravenous virus administration, 161011 vp Ad5CTL in
100 ml PBS was injected into the tail-vein of macrophage-depleted
mice 5 minutes after intravenous administration of 20 mg/kg or
50 mg/kg heparins in 100 ml PBS. Mice were sacrificed and
perfused with PBS 1h post-inoculation. Livers were harvested and
total DNA was purified using the QiaQuick Spin DNA Extraction
Kit as described above.
Analysis of Ad5 localisation in vivo
To characterise Ad localisation in vivo, 161011 vp Alexa-labelled
Ad5CTL in 100 ml PBS was injected into the tail vein 5 minutes
after intravenous administration of 20 mg/kg or 5 0mg/kg
heparins in 100 ml PBS. Livers were flushed by cardiac PBS
perfusion 1 h later to remove non-adherent virus particles and the
largest lobe was then embedded and immediately frozen in OCT
Tissue-Tek embedding compound. Frozen liver sections (4 mm)
were fixed and stained with rat anti-mouse CD31 antibody at a
1:50 dilution (BD Pharmingen, Oxford, UK) to detect endothelial
cells. Specific binding of primary antibodies was visualised using a
goat anti-rat Alexa Fluor 546 (red) secondary antibody in PBS at a
dilution of 1:500. Sections were imaged using an Olympus
imaging system.
Statistical analysis
Statistical significance was calculated using 2-sample, 2-tailed
student’s t-tests. P-values of ,0.05 or over were considered
statistically significant. Results presented are representative data
from a minimum of two separate experiments with at least 3
experimental replicates per group. All virus binding and
transduction experiments were performed in biological triplicates
and on at least three independent occasions. All error bars
represent SEM.
Supporting Information
Figure S1 Analysis of heparinase III pretreatment in vitro. (A)
The expression of intact heparan sulfate (using the 10E4 antibody)
or heparinase III-digested heparan sulfate ‘stubs’ (using the 3G10
antibody) was analysed by flow cytometry in SKOV3 cells that
had been treated with increasing doses of heparinase III (0 U/ml,
0.5 U/ml, 1 U/ml or 5 U/ml) for 1 h at 37uC. Each marker was
tested on at least 3 independent samples and raw traces as well as
quantitative data are shown. Data are presented as average % of
expressing/positive cells +/2 SEM. (B) The expression of
chondroitin sulfate was analysed by flow cytometry in SKOV3
cells that had been treated with increasing doses of heparinase III
or chondroitinase ABC (0 U/ml, 0.5 U/ml, 1 U/ml or 5 U/ml).
At least 3 independent samples were tested and data are presented
as average % of expressing/positive cells +/2 SEM. (C+D)
SKOV3 cells that had been pretreated with increasing doses of
heparinase III (HepIII) for 1 h at 37uC were transduced with 1000
vp/cell of Ad5 in the presence or absence of 10 mg/ml FX. (C)
Binding of 1000 vp/cell Ad5CTL to SKOV3 cells was quantified
after incubation with cells for 1 h at 4uC as described previously.
(D) Adenoviral gene transfer was quantified after incubation of
1000 vp/cell Ad5CTL with SKOV3 cells for 1 h or 3 h at 37uC.
b-galactosidase expression was quantified 48 h post-transduction
and normalised to total protein content. *p,0.05, **p,0.01
compared to control. Error bars represent S.E.M.
Found at: doi:10.1371/journal.ppat.1001142.s001 (1.19 MB TIF)
Figure S2 FX-mediated enhancement of gene transfer in
CARlow and CARhigh cell lines. SKOV3, MDA-MB-231, A549,
SNB19, HT29 or NCI-H522 cells were transduced with 1000 vp/
cell of Ad5CTL (closed bars) or Ad5PD1 (open bars) in the
presence and absence of 10 mg/ml FX for 3 h at 37uC. Results are
shown as FX-mediated fold-enhancement over control conditions
(virus alone). Reporter gene expression was quantified 48 h post-
transduction as described previously. Analysis of each cell type was
performed at least on 3 independent occasions and at least in
triplicate within each experiment.
Found at: doi:10.1371/journal.ppat.1001142.s002 (0.08 MB TIF)
Figure S3 Transport of fluorescently-labelled Ad5CTL and
Ad5KO1 in SKOV3 cells. 10,000 vp/cell of Alexa-labelled
Ad5CTL or Ad5KO1 were allowed to bind cells for 1 h at 4uC
in the presence or absence of 10 mg/ml FX. Cells were then
incubated at 37uC for 0 min to 60 min prior to fixation. Nuclei
were counterstained using DAPI. Images were captured using a
606microscope objective.
Found at: doi:10.1371/journal.ppat.1001142.s003 (2.72 MB TIF)
Figure S4 Transport of fluorescent-labelled Ad5 in the presence
of PKA, PI3K and p38MAPK inhibitors. (A) A549 cells were
incubated with PKA, P13K or p38MAPK inhibitors for 30 min at
37uC then 10,000 vp/cell of Alexa488-labelled Ad5CTL (green
particles) in the presence of FX and the different kinase inhibitors
were allowed to bind cells for 1 h at 4uC, followed by incubation at
37uC for 3 h to allow internalisation and intracellular transport
prior to fixation and staining for the MTOC marker pericentrin
(red). Nuclei were counterstained using DAPI. The PKA inhibitor
H 89 dihydrochloride, the PI3K inhibitor LY 294002 hydrochloride
and the p38MAPK inhibitor SB 203580 hydrochloride were used.
Representative images are shown. (B) Percentage of cells with
colocalisation of fluorescently-labelled Ad5CTL with the MTOC
marker pericentrin in A549 cells was calculated by analysing at least
5 separate 406 microscope fields per experimental condition.
** = p,0.01 compared to Ad5CTL+FX values.
Found at: doi:10.1371/journal.ppat.1001142.s004 (0.68 MB TIF)
Figure S5 Effect of sodium chlorate on Ad5CTL-mediated cell
binding and gene transfer. (A) Sulfated glycosaminoglycan (sGAG)
content of cultured SKOV3 cells pretreated with increasing
concentrations of sodium chlorate (0 mM, 20 mM, 50 mM) was
measured using the Blyscan sulfated GAG assay kit, which
quantitates specific binding of the sulfate-binding cationic dye, 1,
9-dimethylmethylene blue. (B) Binding of 1000 vp/cell Ad5CTL
to SKOV3 cells pretreated with increasing concentrations of
sodium chlorate (0 mM, 20 mM, 50 mM) was quantified after
incubation with cells for 1 h at 4uC as described previously. (C)
MTT assay assessment of cell viability in the presence of
increasing concentrations of sodium chlorate.
liver tissue lysates by quantitative PCR as previously described (n = 7). *p,0.05, **p,0.01. (B) Control (no heparin), heparin or modified heparins were
administered to macrophage-depleted MF1 outbred mice 5 minutes prior to intravenous injection of 161011 vp of fluorescently-labelled Ad5 (green).
Mice were sacrificed 1 h later and livers were fixed then stained for the endothelial marker CD31 to facilitate imaging of the sinusoids in the liver
(red). Nuclei were counterstained using DAPI. Images were captured using a 406microscope objective.
doi:10.1371/journal.ppat.1001142.g007
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Found at: doi:10.1371/journal.ppat.1001142.s005 (0.14 MB
TIF)
Table S1 IC50 values of heparins/heparan sulfate for CAR- or
av integrin binding-mutant adenoviruses (mg/ml). SKOV3 cells
were transduced with 1000 vp/cell of Ad5KO1 or Ad5PD1 in the
presence or absence of 10 mg/ml FX and varying concentrations
of heparins/heparan sulfates for 3 h at 37uC. Reporter gene
expression was quantified 48 h post-transduction as described
previously. IC50 values were calculated using the Hill-Slope model.
Found at: doi:10.1371/journal.ppat.1001142.s006 (0.03 MB
DOC)
Acknowledgments
We thank Gregor Aitchison and Nicola Britton for technical assistance,
Gwyn Gould (University of Glasgow) for guidance on confocal imaging
and John Marshall (Institute of Cancer, Barts and the London School of
Medicine and Dentistry) for advice relating to the analysis of integrin
knockdown by flow cytometry.
Author Contributions
Conceived and designed the experiments: ACB ALP SAN AHB.
Performed the experiments: ACB ALP MRD LC. Analyzed the data:
ACB ALP MRD AHB. Contributed reagents/materials/analysis tools:
NvR VMK. Wrote the paper: ACB SAN AHB.
References
1. Russell WC (2009) Adenoviruses: update on structure and function. J Gen Virol
90: 1–20.
2. Hong JY, Lee HJ, Piedra PA, Choi EH, Park KH, et al. (2001) Lower
respiratory tract infections due to adenovirus in hospitalized Korean children:
epidemiology, clinical features, and prognosis. Clin Infect Dis 32: 1423–1429.
3. Echavarria M (2008) Adenoviruses in immunocompromised hosts. Clin
Microbiol Rev 21: 704–715.
4. Kojaoghlanian T, Flomenberg P, Horwitz MS (2003) The impact of adenovirus
infection on the immunocompromised host. Rev Med Virol 13: 155–171.
5. Blackwell Munsgardt (2004) Adenovirus. Am J Transplant 4 Suppl 10: 101–104.
6. Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, et al. (2003)
Molecular monitoring of adenovirus in peripheral blood after allogeneic bone
marrow transplantation permits early diagnosis of disseminated disease. Blood
102: 1114–1120.
7. Munoz FM, Piedra PA, Demmler GJ (1998) Disseminated adenovirus disease in
immunocompromised and immunocompetent children. Clin Infect Dis 27:
1194–1200.
8. Leruez-Ville M, Minard V, Lacaille F, Buzyn A, Abachin E, et al. (2004) Real-
time blood plasma polymerase chain reaction for management of disseminated
adenovirus infection. Clin Infect Dis 38: 45–52.
9. Takayama R, Hatakeyama N, Suzuki N, Yamamoto M, Hayashi T, et al. (2007)
Quantification of adenovirus species B and C viremia by real-time PCR in adults
and children undergoing stem cell transplantation. J Med Virol 79: 278–284.
10. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al.
(1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses
2 and 5. Science 275: 1320–1323.
11. Law LK, Davidson BL (2005) What does it take to bind CAR? Mol Ther 12:
599–609.
12. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v
beta 3 and alpha v beta 5 promote adenovirus internalization but not virus
attachment. Cell 73: 309–319.
13. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR (1994) Integrin alpha v
beta 5 selectively promotes adenovirus mediated cell membrane permeabiliza-
tion. J Cell Biol 127: 257–264.
14. Alemany R, Curiel DT (2001) CAR-binding ablation does not change
biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347–1353.
15. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, et al. (2003) Simultaneous
CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism.
Mol Ther 8: 485–494.
16. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, et al. (2004) Effect of
adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats.
Mol Ther 10: 344–354.
17. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, et al.
(2006) Multiple vitamin K-dependent coagulation zymogens promote adenovi-
rus-mediated gene delivery to hepatocytes. Blood 108: 2554–2561.
18. Di Paolo NC, Shayakhmetov DM (2009) Adenovirus de-targeting from the liver.
Curr Opin Mol Ther 11: 523–531.
19. Coyne CB, Bergelson JM (2005) CAR: a virus receptor within the tight junction.
Adv Drug Deliv Rev 57: 869–882.
20. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, et al. (2008)
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.
Proc Natl Acad Sci U S A 105: 5483–5488.
21. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008)
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397–409.
22. Madisch I, Wolfel R, Harste G, Pommer H, Heim A (2006) Molecular
identification of adenovirus sequences: a rapid scheme for early typing of human
adenoviruses in diagnostic samples of immunocompetent and immunodeficient
patients. J Med Virol 78: 1210–1217.
23. Kampmann B, Cubitt D, Walls T, Naik P, Depala M, et al. (2005) Improved
outcome for children with disseminated adenoviral infection following allogeneic
stem cell transplantation. Br J Haematol 130: 595–603.
24. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest
108: 169–173.
25. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans fine-
tune mammalian physiology. Nature 446: 1030–1037.
26. Endress T, Lampe M, Briggs JA, Krausslich HG, Brauchle C, et al. (2008) HIV-
1-cellular interactions analyzed by single virus tracing. Eur Biophys J 37:
1291–1301.
27. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of
heparan sulfate in attachment to and infection of the murine female genital tract
by human papillomavirus. J Virol 83: 2067–2074.
28. Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:
1438–1445.
29. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, et al. (1999) A novel role for
3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99: 13–22.
30. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A (2005) Adenovirus binding
to blood factors results in liver cell infection and hepatotoxicity. J Virol 79:
7478–7491.
31. Lyon M, Deakin JA, Gallagher JT (1994) Liver heparan sulfate structure. A
novel molecular design. J Biol Chem 269: 11208–11215.
32. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, et al. (2007)
Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich
lipoproteins independently of LDL receptor family members. J Clin Invest 117:
153–164.
33. Vongchan P, Warda M, Toyoda H, Toida T, Marks RM, et al. (2005) Structural
characterization of human liver heparan sulfate. Biochim Biophys Acta 1721:
1–8.
34. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S (2009) Heparan sulfate
proteoglycans are required for cellular binding of the hepatitis E virus ORF2
capsid protein and for viral infection. J Virol 83: 12714–12724.
35. Tiwari V, O’Donnell CD, Oh MJ, Valyi-Nagy T, Shukla D (2005) A role for 3-
O-sulfotransferase isoform-4 in assisting HSV-1 entry and spread. Biochem
Biophys Res Commun 338: 930–937.
36. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, et al. (2002) The
therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a
low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38:
1917–1926.
37. Boyle MP, Enke RA, Reynolds JB, Mogayzel PJ, Jr., Guggino WB, et al. (2006)
Membrane-associated heparan sulfate is not required for rAAV-2 infection of
human respiratory epithelia. Virol J 3: 29.
38. O’Donnell J, Taylor KA, Chapman MS (2009) Adeno-associated virus-2 and its
primary cellular receptor–Cryo-EM structure of a heparin complex. Virology
385: 434–443.
39. Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M (2003) Heparan
sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackie-
virus B3 PD infection. J Virol 77: 10071–10077.
40. Shayakhmetov DM, Eberly AM, Li ZY, Lieber A (2005) Deletion of penton
RGD motifs affects the efficiency of both the internalization and the endosome
escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs.
J Virol 79: 1053–1061.
41. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, et al. (2003)
Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum
Gene Ther 14: 777–787.
42. Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, et al. (1999)
CAR-dependent and CAR-independent pathways of adenovirus vector-
mediated gene transfer and expression in human fibroblasts. J Clin Invest 103:
579–587.
43. Greber U, Puntener D (2009) DNA tumour virus entry- from plasma membrane
to the nucleus. Semin Cell Dev Biol 20: 631–642.
44. Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, et al. (1999)
Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate.
J Biol Chem 274: 36267–36273.
45. Esko JD, Weinke JL, Taylor WH, Ekborg G, Roden L, et al. (1987) Inhibition of
chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell
mutants defective in galactosyltransferase I. J Biol Chem 262: 12189–12195.
46. Bame KJ, Esko JD (1989) Undersulfated heparan sulfate in a Chinese hamster
ovary cell mutant defective in heparan sulfate N-sulfotransferase. J Biol Chem
264: 8059–8065.
Receptor Requirements for FX-Mediated Ad Infection
PLoS Pathogens | www.plospathogens.org 16 October 2010 | Volume 6 | Issue 10 | e1001142
47. Bai X, Esko JD (1996) An animal cell mutant defective in heparan sulfate
hexuronic acid 2-O-sulfation. J Biol Chem 271: 17711–17717.
48. Basu A, Kanda T, Beyene A, Saito K, Meyer K, et al. (2007) Sulfated
homologues of heparin inhibit hepatitis C virus entry into mammalian cells.
J Virol 81: 3933–3941.
49. Xu Z, Tian J, Smith JS, Byrnes AP (2008) Clearance of adenovirus by Kupffer
cells is mediated by scavenger receptors, natural antibodies, and complement.
J Virol 82: 11705–11713.
50. Smith JS, Xu Z, Tian J, Stevenson SC, Byrnes AP (2008) Interaction of
systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum
Gene Ther 19: 547–554.
51. Shashkova EV, Doronin K, Senac JS, Barry MA (2008) Macrophage depletion
combined with anticoagulant therapy increases therapeutic window of systemic
treatment with oncolytic adenovirus. Cancer Res 68: 5896–5904.
52. Di Paolo NC, van Rooijen N, Shayakhmetov DM (2009) Redundant and
synergistic mechanisms control the sequestration of blood-born adenovirus in the
liver. Mol Ther 17: 675–684.
53. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG (1992) Cell
surface receptors for herpes simplex virus are heparan sulfate proteoglycans.
J Cell Biol 116: 1273–1281.
54. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, et al. (2003) Cellular
binding of hepatitis C virus envelope glycoprotein E2 requires cell surface
heparan sulfate. J Biol Chem 278: 41003–41012.
55. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, et al. Reengineering a
receptor footprint of adeno-associated virus enables selective and systemic gene
transfer to muscle. Nat Biotechnol 28: 79–82.
56. Perabo L, Goldnau D, White K, Endell J, Boucas J, et al. (2006) Heparan sulfate
proteoglycan binding properties of adeno-associated virus retargeting mutants
and consequences for their in vivo tropism. J Virol 80: 7265–7269.
57. Stanford KI, Wang L, Castagnola J, Song D, Bishop JR, et al. Heparan sulfate
2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol
Chem 285: 286–294.
58. Sakai T, Kisiel W (1990) Binding of human factors X and Xa to HepG2 and J82
human tumor cell lines. Evidence that factor Xa binds to tumor cells
independent of factor Va. J Biol Chem 265: 9105–9113.
59. Kazama Y, Komiyama Y, Kisiel W (1993) Tissue factor pathway inhibitor and
protease nexin-1 are major factor Xa binding proteins on the HepG2 cell
surface. Blood 81: 676–682.
60. Craft J, Epps K, Brancato S, Serfis A (2003) Incorporation of blood clotting
factor X into phospholipid model membranes: fluorescence microscopy imaging
and subphase effects surrounding the lipid phase transition region. Journal of
Colloid and Interface Science 268: 181–187.
61. Sabharwal AK, Padmanabhan K, Tulinsky A, Mathur A, Gorka J, et al. (1997)
Interaction of calcium with native and decarboxylated human factor X. Effect of
proteolysis in the autolysis loop on catalytic efficiency and factor Va binding.
J Biol Chem 272: 22037–22045.
62. Scandura JM, Ahmad SS, Walsh PN (1996) A binding site expressed on the
surface of activated human platelets is shared by factor X and prothrombin.
Biochemistry 35: 8890–8902.
63. Plescia J, Altieri DC (1996) Activation of Mac-1 (CD11b/CD18)-bound factor X
by released cathepsin G defines an alternative pathway of leucocyte initiation of
coagulation. Biochem J 319(Pt 3): 873–879.
64. Tuve S, Wang H, Jacobs JD, Yumul RC, Smith DF, et al. (2008) Role of cellular
heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and
35. PLoS Pathog 4: e1000189.
65. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, et al. (2007) Adenovirus
5 fibers mutated at the putative HSPG-binding site show restricted retargeting
with targeting peptides in the HI loop. Mol Ther 15: 741–749.
66. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, et al. (2009)
Identification of coagulation factor (F)X binding sites on the adenovirus serotype
5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114:
965–971.
67. Rezaie AR (1998) Calcium enhances heparin catalysis of the antithrombin-factor
Xa reaction by a template mechanism. Evidence that calcium alleviates Gla
domain antagonism of heparin binding to factor Xa. J Biol Chem 273:
16824–16827.
68. Rezaie AR (2000) Identification of basic residues in the heparin-binding exosite
of factor Xa critical for heparin and factor Va binding. J Biol Chem 275:
3320–3327.
69. Ghosh T, Chattopadhyay K, Marschall M, Karmakar P, Mandal P, et al. (2009)
Focus on antivirally active sulfated polysaccharides: from structure-activity
analysis to clinical evaluation. Glycobiology 19: 2–15.
70. Huskens D, Vermeire K, Profy AT, Schols D (2009) The candidate sulfonated
microbicide, PRO 2000, has potential multiple mechanisms of action against
HIV-1. Antiviral Res 84: 38–47.
71. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ (2006) Candidate
polyanion microbicides inhibit HIV-1 infection and dissemination pathways in
human cervical explants. Retrovirology 3: 46.
72. Von Seggern DJ, Kehler J, Endo RI, Nemerow GR (1998) Complementation of
a fibre mutant adenovirus by packaging cell lines stably expressing the
adenovirus type 5 fibre protein. J Gen Virol 79(Pt 6): 1461–1468.
Receptor Requirements for FX-Mediated Ad Infection
PLoS Pathogens | www.plospathogens.org 17 October 2010 | Volume 6 | Issue 10 | e1001142
